A Phase 2, Open-label, Single-Agent, Multicenter Study to Evaluate the
Efficacy and Safety of INCB054828 in Subjects with Metastatic or Surgically Unresectable Urothelial Carcinoma Haboring FGF/FGFR Alterations, NCT02872714
PURPOSE OF THIS CLINICAL RESEARCH TRIAL
The purpose of this study is to evaluate the overall response rate (ORR) of pemigatinib as a monotherapy in the treatment of metastatic or surgically unresectable urothelial carcinoma harboring FGF/FGFR alterations.
MORE DETAILS ON THIS TRIAL
15228 / NCT02872714 / STAR / Open 10-23-2018
TRIAL AVAILABLE AT THESE LOCATIONS